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Type 1 neovascularization may confer 
resistance to geographic atrophy amongst eyes 
treated for neovascular age‑related macular 
degeneration
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Abstract 
Background: To report a series of age‑related macular degeneration (AMD) patients in whom progression to geo‑
graphic atrophy (GA) in one eye receiving frequent intravitreal injections of anti‑vascular endothelial growth factor (anti‑
VEGF) therapy for type 1 neovascularization (NV) was slower than that of the fellow eye with non‑neovascular AMD.
Methods: Retrospective, observational case series examining the clinical course and GA progression rate in four 
consecutive patients in which one eye harbored type 1 neovascular AMD and was receiving anti‑VEGF therapy, while 
the fellow eye manifested signs of non‑neovascular AMD only. Eligibility criteria included anti‑VEGF therapy duration 
of over 4 years and over 50 injections. Lesion evolution was documented via multimodal imaging. GA at baseline and 
final visits was quantified and GA progression rate for each eye was determined.
Results: Four consecutive patients were followed for a mean interval of 94 months (range 62–120). One eye har‑
bored type 1 NV while the fellow eye remained non‑neovascular. The former received a mean of 65.5 ± 15.2 anti‑VEGF 
injections. Mean rate of GA progression in non‑neovascular eyes was 0.076 ± 0.024 mm2/month and in type 1 NV 
eyes was 0.004 ± 0.005 mm2/month. Difference in GA progression rate between type 1 and non‑neovascular eyes 
was found to be statistically significant (P = 0.001).
Conclusions: These findings support previous hypotheses that, unlike type 2 and 3 lesions, type 1 NV may represent 
a neovascular AMD subtype more resilient to GA formation. This may have implications for anti‑VEGF regimens in the 
management of type 1 NV.
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Background
Geographic atrophy (GA) is a form of advanced age-
related macular degeneration (AMD) and is a term 
that is used to denote the occurrence of retinal pig-
ment epithelium (RPE), photoreceptor and choriocap-
illaris loss [1, 2]. Central GA, with resultant disruption 
of foveal architecture, is typically characterized by 
poor visual function [3]. There is great interest in the 
pathophysiological mechanisms that govern the rate 
of GA progression as well as the iatrogenic and treat-
ment-induced factors that accelerate or retard its 
progression. With regard to non-neovascular AMD, 
drusen characteristics have been used to stratify the 
risk of GA development [4]. In the neovascular form 
of AMD, the subtype of neovascularization [5, 6] clas-
sified with either fluorescein angiography (FA) alone 
[as poorly defined (occult), well-defined (classic) or as 
retinal angiomatous proliferation (RAP)] or anatomi-
cally using both FA and OCT (as type 1—sub retinal 
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pigment epithelium, type 2—subretinal, or type 3—
intraretinal) is believed to influence the risk of GA 
progression [7].
Recently, results from the comparison of AMD treat-
ment trials (CATT) study and Inhibition of VEGF 
in age-related choroidal neovascularization (IVAN) 
trial have raised some concerns regarding the effects 
of long-term anti-vascular endothelial growth factor 
(VEGF) therapy on the outer retina [8]. The results 
from both of these studies have suggested that the 
duration and frequency of anti-VEGF therapy may be 
related to the risk of new GA and GA progression. One 
way by which long-term anti-VEGF therapy may accel-
erate the rate of GA progression is by nullifying VEGF 
activity in the outer retina beyond the physiological 
concentrations that are required for homeostatic func-
tion. Causal relationships between GA and anti-VEGF 
therapy demonstrated in the CATT and IVAN stud-
ies have been supported by experimental work in mice 
where the absence of soluble VEGF isoforms resulted 
in the development of choroidal atrophy and attenua-
tion/loss of RPE [9]. The net effect of these experimen-
tal changes was photoreceptor death and a decline in 
visual function [9]. The risk of GA atrophy following 
anti-VEGF therapy is, however, not independent of 
NV subtype. In a recent study by Xu et  al. [7], it was 
shown that eyes harboring type 1 neovascularization 
(NV) were associated with a relatively lower risk of 
GA formation and progression. In contrast, type 3 NV 
eyes were at a considerably higher risk of GA forma-
tion. Another study by Chae et al., also found that eyes 
with neovascular AMD that had type 1 NV at baseline, 
had a more favorable long-term visual prognosis on a 
treat-and-extend regimen of anti-VEGF agents [10]. 
Expanding our understanding about the clinical and 
multimodal imaging (MMI) characteristics of NV sub-
types and the relationships that they bear to the devel-
opment of GA is therefore likely to aid with a more 
individualized patient management.
In this report we describe the clinical and MMI charac-
teristics of 4 patients who developed a greater degree of 
GA in the eye that manifested signs of non-neovascular 
AMD relative to the contralateral eye that was receiving 
frequent anti-VEGF injections for type 1 NV. These find-
ings are used to speculate upon the potentially protective 
role of sub-RPE neovascular tissue in reducing the rate of 
GA progression.
Methods
This retrospective cohort study design was approved by 
the Western Institutional Review Board (Olympia, WA, 
USA). It complied with the Health Insurance Portability 
and Accountability Act of 1996 and followed the Tenets 
of the Declaration of Helsinki.
Consecutive patients with neovascular AMD that met 
the eligibility criteria were enrolled into the study in a ret-
rospective manner. Patients included in this study met all 
of the following inclusion criteria: (1) Frequent and con-
tinuous anti-VEGF treatment for type 1 NV was being 
administered to one eye for 4 or more years. (2) 50 or 
more injections of anti-VEGF therapy had been admin-
istered to the eye with type 1 NV. (3) The eye receiving 
anti-VEGF therapy was treatment-naïve at the initiation 
of treatment and had not received steroids, laser or other 
treatments. (4) The fellow eye manifested signs of non-
neovascular AMD for the duration of the study. Exclu-
sionary criterion was the presence of neovascular AMD 
in the fellow eye.
All patients were followed and treated by a sin-
gle retina specialist (KBF) between January 2004 and 
January 2015. However, the date of the first injection 
was considered the baseline study visit. The follow-
ing data were recorded from each patient: age, gen-
der, ocular and systemic comorbidities, concurrent 
medications, type and number of anti-VEGF injec-
tions administered to the eye with type 1 NV, interval 
at which they were treated, and best corrected Snellen 
visual acuity at baseline and at last follow-up to-date 
(using the patient’s current spectacles with and with-
out pinholes). Multimodal imaging results including 
color photographs, fluorescein angiography (FA), fun-
dus autofluorescence (AF), near-infrared reflectance 
(IR) and spectral-domain optical coherence tomogra-
phy (SD-OCT) were reviewed. The anatomical clas-
sification of the neovascular lesion was determined 
using FA and SD-OCT by an unmasked, independ-
ent grader. Wide field (488  nm) AF and color fundus 
images were acquired with the TRC-501X fundus cam-
era (Topcon Imagenet, Tokyo, Japan). Thus, all GA 
measurements were done through the same software. 
SD-OCT and IR images were obtained using the Hei-
delberg Spectralis HRA + OCT (Heidelberg Engineer-
ing, Inc, Vista, CA, USA). The AutoRescan function of 
the Spectralis platform permitted accurate alignment 
of SD-OCT scans between visits and facilitated reli-
able longitudinal comparisons.  The Heidelberg Spec-
tralis HRA  +  OCT permitted AF or IR images to be 
simultaneously obtained with registered eye-tracking 
and thus facilitated reliable comparisons between 
baseline and follow-up visits. The areas of GA forma-
tion at baseline and last follow-up were outlined in 
each of the eight eyes of the four patients. Progression 
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of GA was defined as de novo development of atro-
phy or an enlargement of the preexisting area(s) of 
GA (dark pixels) compared to baseline. Measure-
ments of the total area of regions of GA were made 
and assessed manually on scaled AF images from the 
Topcon IMAGEnet i-base software. The differences 
in total GA area between the last visit and the base-
line were calculated and the rate of progression was 
determined by dividing the difference in GA size (in 
mm2 units) by the time between the baseline and last 
visits (expressed in months). In eyes with type 1 NV, 
the rate of progression was standardized to the num-
ber of injections received by dividing the difference in 
GA size between baseline and final visits by the total 
number of injections administered. A two-tailed t test 
was used to determine if the rate of GA progression 
(expressed in mm2/month) was different between the 
eye with non-neovascular manifestations and the eye 
with type 1 NV receiving anti-VEGF therapy. The out-
lining of GA lesion edges for qualitative analyses and 
figure preparation was conducted in Photoshop CS3 




The mean follow-up interval for 4 patients (1 male 
and 3 female) with a mean age of 85.5  years (range 
76–95) was 93.75  months (range 64–120). The mean 
number of anti-VEGF injections administered to the 
eye with type 1 NV was 65.5  ±  15.2. The mean rate 
of GA progression in the non-neovascular eye was 
0.076 ±  0.024  mm2/month and in the eye with type 1 
NV was 0.004 ±  0.005  mm2/month. The difference in 
the rate of GA progression between neovascular and 
non-neovascular eyes was found to be statistically sig-
nificant (P = 0.001).
The demographics, features of treatment regimen and 
progression characteristics for GA in each eye are pro-
vided in Table 1. In all four patients, the right eye was 
receiving treatment with anti-VEGF for type 1 NV and 
the left eye expressed manifestations of non-neovas-
cular AMD. MMI findings for each of the patients in 
this study are provided in Figs. 1, 2, 3, 4, 5, 6, 7 and 8. 
Detailed case descriptions for each patient are provided 
below.
Case 1
A 77-year-old white male with a history of hyperten-
sion, hyperlipidemia and benign prostate hyperplasia 
was started on intravitreal anti-VEGF therapy for active 
type 1 NV in his right eye. His ocular comorbidities 
included pseudoexfoliation syndrome, mild nuclear 
sclerosis cataracts, posterior vitreous detachment bilat-
erally and a choroidal nevus in the nasal retina. Visual 
acuities at baseline were 20/30 + 2 in the right eye and 
20/40 in the left eye. Results of MMI on the initial visit 
are provided in Fig. 1. Of note, the right eye presented 
with an area of juxtafoveal GA which was at least 
five times larger than the spot of GA observed supe-
rior to the fovea in the left eye. Type 1 NV developed 
in the right eye and was treated with 81 intravitreal 
Table 1 Summary of patient demographic data, lesion type, treatment regimen and geographic atrophy progression
WM white male, WF white female, OD right eye, OS left eye, CNV choroidal neovascularization, mm2 millimeter2, ΔGA change in geographic atrophy
Eye Patient 1 (77, WM) Patient 2 (76, WF) Patient 3 (94, WF) Patient 4 (95, WF)
OD OS OD OS OD OS OD OS
Injections received 81 ranibizumab – 18 ranibizumab; 36 
aflibercept
– 51 ranibizumab – 6 bevacizumab; 70 
ranibizumab
–
NV Type 1 – Type 1 – Type 1 – Type 1 –
Regimen schedule q6 weeks – q6–7 weeks – q7–8 weeks – q4–5 weeks –
Total follow‑up interval 120 months 62 months 99 months 95 months
Initial visit (mm2) 0.38 0.05 0.00 0.00 0.00 0.00 0.56 4.62
Last visit (mm2) 1.73 9.65 0.30 6.72 0.07 5.72 0.61 7.84
ΔGA Last − Initial 1.35 9.60 0.30 6.72 0.07 5.72 0.05 3.22
Progression rate 1 of GA 
(mm2/month)
0.01125 0.08 0.00483 0.10838 0.00070 0.05777 0.00052 0.03389
Progression rate 2 of GA 
(mm2/injection)
0.01666 – 0.00555 – 0.00137 – 0.00065 –
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anti-VEGF injections over the subsequent 120 months 
on a treat-and-extend-regimen (TER). Injections were 
given approximately every 5–7  weeks. At the most 
recent follow-up, visual acuity was 20/50  +  2 in the 
right eye and 20/400 in the left eye (Fig. 2). The area of 
GA at baseline visit was 0.38 mm2 for the right eye and 
0.05 mm2 for the left eye. The area of GA at final visit 
was 1.73  mm2 for the right eye and 9.65  mm2 for the 
left eye. The rate of GA progression was 0.01125 mm2/
month (or 0.01666  mm2/anti-VEGF injection) for the 
right eye and 0.08 mm2/month for the left eye.
Case 2
A 76-year-old white female with a history of hyperten-
sion and hyperlipidemia was started on intravitreal anti-
VEGF therapy for active type 1 NV in her right eye. Her 
Fig. 1 Patient 1 at presentation. Color fundus (a) and fundus autofluorescence images (b) demonstrate geographic atrophy at the infero‑temporal 
aspect of the right macula and a small atrophic spot at the superior aspect of the left macula (arrowheads). Speckled areas of hyper‑ and hypo‑auto‑
fluorescence can also be seen at the nasal aspect of the optic discs bilaterally. Insets provide high magnification views of the macula where regions 
of atrophy have been demarcated (yellow lines)
Page 5 of 12Dhrami‑Gavazi et al. Int J Retin Vitr  (2015) 1:15 
ocular comorbidities included bilateral retinal breaks 
treated with laser retinopexy, bilateral narrow ante-
rior chamber angles treated with laser iridotomies, and 
bilateral mild nuclear sclerotic cataracts. Visual acuities 
at baseline were 20/25 + 2 in the right eye and 20/25 in 
the left eye. The baseline MMI of the right eye, includ-
ing FA (not shown) demonstrated type 1 NV with over-
lying subretinal fluid. In the left eye there were drusen, 
reticular pseudodrusen, and a small subfoveal acquired 
vitelliform lesion (Fig.  3). Neither eye manifested GA 
at baseline. Over the following 62 months, the right eye 
received 54 intravitreal anti-VEGF injections on a TER 
with injections given approximately every 5–7 weeks. At 
the most recent follow-up, visual acuity was 20/30 − 2 in 
the right eye and 20/200 in the left eye. The area of GA at 
baseline visit was 0 mm2 for both eyes. The area of GA at 
final visit was 0.30 mm2 for the right eye and 6.72 mm2 
for the left eye (Fig. 4). The rate of GA progression was 
0.00483 mm2/month (or 0.00555 mm2/anti-VEGF injec-
tion) for the right eye and 0.10838  mm2/month for the 
left eye.
Case 3
A 94-year-old white female with a history of hyperten-
sion and spinal stenosis was started on intravitreal anti-
VEGF therapy for active type 1 NV in her right eye. 
Her ocular comorbidities included primary open angle 
glaucoma that was managed with latanoprost drops in 
Fig. 2 Clinical course of Patient 1. Serial spectral‑domain optical coherence tomography (SD‑OCT) images taken approximately every 2 years dem‑
onstrate relative preservation of outer retinal structures in the right eye (left panel) and progressive atrophy in the left eye (right panel). Color fundus 
and fundus autofluorescence images acquired at the final visit demonstrate a greater area of atrophy in the left eye relative to the right. SD‑OCT 
images of the final visit reveal persistent intraretinal edema from type 1 NV in the right eye
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both eyes. The patient was pseudophakic and had mild 
epiretinal membranes bilaterally. Visual acuities at base-
line were 20/30 in each eye. At baseline the right eye 
demonstrated type 1 neovascular AMD and the left eye 
had an acquired, juxtafoveal vitelliform lesion in addi-
tion to drusen and pigment clumping (Fig.  5). FA (not 
shown) demonstrated type 1 NV with overlying subreti-
nal fluid. Neither eye manifested GA at baseline. Over 
the following 99 months, the right eye received 51 intra-
vitreal anti-VEGF injections on a TER with injections 
given approximately every 6–7  weeks. At the final visit 
of this study, the BCVA was 20/60 −  2 in the right eye 
Fig. 3 Patient 2 at presentation. Color fundus (a) and fundus autofluorescence (b) images demonstrate the absence of geographic atrophy at the 
baseline visit. Reticular pseudodrusen and mottled retinal pigment epithelial changes are evident bilaterally. Spectral‑domain optical coherence 
tomography images (c) demonstrate subretinal fluid and type 1 neovascularization in the right eye. A vitelliform lesion is present in the left fovea
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and 20/200 in the left eye. The area of GA at baseline visit 
was 0 mm2 for both eyes. The area of GA at final visit was 
0.07 mm2 for the right eye and 5.72 mm2 for the left eye 
(Fig.  6). The rate of GA progression was 0.00070  mm2/
month (or 0.00137  mm2/anti-VEGF injection) for the 
right eye and 0.05777 mm2/month for the left eye.
Case 4
A 95-year-old white female with a history of hyperten-
sion was commenced on intravitreal anti-VEGF therapy 
for active type 1 NV in her right eye. Her ocular comor-
bidities included bilateral mild nuclear sclerotic cata-
racts. Visual acuities at baseline were 20/25  +  2 in the 
right eye and 20/40 in the left eye. The baseline MMI 
of the right eye including FA (not shown) demonstrated 
type 1 NV with overlying subretinal and intraretinal 
fluid and two small juxtafoveal spots of GA in the right 
eye and a few extramacular drusen. Intermediate sized, 
refractile drusen and 4 areas of GA were seen in the left 
eye (Fig. 7). Over the following 95 months, the right eye 
received 76 intravitreal anti-VEGF injections on a TER 
with injections given approximately every 5–7 weeks. At 
the most recent follow-up, visual acuity was 20/30 − 2 in 
the right eye and 20/200 − 1 in the left eye. The area of 
GA at baseline visit was 0.56 mm2 for the right eye and 
4.62 mm2 for the left eye. The area of GA at final visit was 
0.61 mm2 for the right eye and 7.84 mm2 for the left eye 
(Fig.  8). The rate of GA progression was 0.00052  mm2/
month (or 0.00065  mm2/anti-VEGF injection) on the 
right eye and 0.03389 mm2/month on the left eye.
Discussion
The relationship between neovascular subtypes, anti-
VEGF dosing regimen and the development of GA in 
Fig. 4 Clinical course of Patient 2. Serial spectral‑domain optical coherence tomography (SD‑OCT) images taken approximately every 2 years dem‑
onstrate resolution of subretinal fluid and preservation of outer retinal structures in the right eye (left panel) and reabsorption of vitelliform material, 
thinning of the choriocapillaris, retinal pigment epitheium and photoreceptor layer in the left eye (right panel). Color fundus and fundus autofluo‑
rescence images acquired at the final visit demonstrate a greater area of atrophy in the left eye relative to the right. SD‑OCT images of the final visit 
reveal persistent type 1 NV in the right eye
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AMD is complex [7, 11, 12]. Although anti-VEGF ther-
apy has become the mainstay treatment for neovascu-
lar AMD, there have been some concerns regarding the 
long-term effects of these agents on outer retinal struc-
tures. Recent analyses of GA data from the CATT and 
IVAN studies have suggested that more frequent dosing 
of anti-VEGF agents may be associated with an increased 
risk of new GA and a greater rate of GA progression [8, 
13]. Lois et  al. monitored GA progression using a simi-
lar methodology to our series and concluded that each 
additional injection of anti-VEGF increased the odds of 
GA development by a factor of 1.35 [14]. To date how-
ever, a difference in the rate of GA progression between 
ranibizumab and bevacizumab has not been proven [13].
The prospective study performed by Xu and colleagues 
demonstrated that the risk of GA progression has impor-
tant correlations to the subtype of NV that is being 
treated. Upon analyzing the risk factors associated with 
the development of GA, Grunwald et  al. [8] observed 
that RAP lesions were associated with a 1.69 greater risk 
Fig. 5 Patient 3 at presentation. As noted on color photographs (a) and fundus autofluorescence (b), neither eye had geographic atrophy. Mild 
non‑neovascular AMD changes consisting of drusen and pigment mottling were present in the right eye while a juxtafoveal acquired vitelliform 
lesion was present in the left eye, in addition to somewhat denser drusen and pigment clumping
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of GA development, a finding that supports a previous 
report from McBain et al. [11]. Analysis of data from the 
CATT study also revealed that the presence of intraretinal 
fluid was associated with a two-fold risk of GA formation, 
while an increase in subretinal fluid and sub-RPE tissue 
thickness conferred a decreased risk of GA formation [8]. 
One could speculate that the presence of intraretinal fluid 
is not a risk factor but rather a consequence of irrevers-
ible damage to the outer retina. Our findings, however, 
suggest that the presence of neovascular tissue in the 
sub-RPE space may confer a protective effect against the 
development of GA. It is plausible that proliferation of 
vascular tissue adjacent to the retinal pigment epithelium, 
although pathologic, may serve to nourish the RPE layer 
and thus preserve outer retinal structures.
In AMD, development of neovascularization in one 
eye is a strong predictor for the development of NV in 
the fellow eye [15]. The risk of the fellow eye developing 
NV is also related to the duration of AMD. Therefore, it 
is uncommon for patients with AMD with NV in one eye 
not to have NV of the fellow eye after a follow-up period 
of almost 10 years. For this reason, the patients included 
in this case series represent an ideal experimental model 
to study AMD because the pathogenic factors that mod-
ulate the course of this disease, including genetics, envi-
ronmental exposure and diet, are expected to have an 
equal influence on the non-neovascular and neovascular 
eyes of the same patient. Patients included in this case 
series, therefore, allow us to assess the temporal relation-
ship between the phenotypic manifestations of AMD, the 
iatrogenic influence of intraocular therapies and the risk 
of GA progression in the absence of other confounding 
factors.
Work by Sunness and colleagues and also the results 
of the CATT study have shown that there is strong con-
cordance in the rate of GA development between eyes of 
the same patient [16, 17]. The significant disparity in the 
rate of GA development in this series, which was found 
to be statistically significant, would suggest that a patho-
genic mechanism that was unique to the neovascular eye 
Fig. 6 Clinical course of Patient 3. Serial spectral‑domain optical coherence tomography (SD‑OCT) images taken approximately every 2 years dem‑
onstrate gradual progression of central geographic atrophy in the left eye (right panel) and minimal progression of foveal atrophy in the right eye 
(left panel). The marked difference between the left and right eyes with respect to the area of atrophy (yellow lines) is illustrated in color fundus and 
fundus autofluorescence images that were acquired at the most recent visit. SD‑OCT of the right eye at the final visit reveals persistent type 1 NV
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was reducing the rate of GA progression. This finding is 
inconsistent with previous reports that found the risk of 
GA progression to be positively correlated with the num-
ber of anti-VEGF injections [13, 16]. The mean number 
of anti-VEGF injections per eye in this series was 65 and 
one would expect an increased rate of GA progression in 
the eyes receiving treatment. However, we observed the 
converse effect. Taken together, these findings suggest 
that type 1 neovascular tissue may serve a protective role 
and might reduce the rate of GA progression in AMD.
Conclusions
Currently, there remains some debate concerning the 
most efficacious treatment strategy for the manage-
ment of neovascular AMD [18]. The observations in 
this small series support previous speculations that 
type 1 NV may reduce the risk of GA progression. 
From a clinical standpoint, it may therefore be advan-
tageous to have neovascular tissue in the sub-RPE 
space, and regimens that aim to achieve total regres-
sion of type 1 NV may be associated with greater 
Fig. 7 Patient 4 at presentation. Areas of geographic atrophy (yellow lines) are clearly evident on color fundus (a) and fundus autofluorescence 
images (b) of the left and right eyes. Spectral‑domain optical coherence (SD‑OCT) images (c) taken of the right eye (top) and left eye (bottom) 
at the initiation of anti‑vascular endothelial therapy for the right eye. The scans show subretinal and intraretinal fluid in the right eye and normal 
subfoveal findings in the left eye
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visual morbidity in the long-term. We acknowledge 
that more quantitative data is necessary to validate 
these findings.
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